|Articles|April 5, 2023 (Updated: April 25, 2023)
Pharma USA 2023: IRA Impact on Patients
Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes to Medicare and how it positively effects patients.
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on Medicare patients' affordability.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Pharmaceutical Executive Daily: FDA Approves Hernexeos
3
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
4
FDA Approves Hernexeos Under National Priority Voucher Program
5